Eliseev Platon, Balantcev Grigory, Nikishova Elena, Gaida Anastasia, Bogdanova Elena, Enarson Donald, Ornstein Tara, Detjen Anne, Dacombe Russell, Gospodarevskaya Elena, Phillips Patrick P J, Mann Gillian, Squire Stephen Bertel, Mariandyshev Andrei
Northern State Medical University, Arkhangelsk, Russian Federation.
Northern Arctic Federal University, Arkhangelsk, Russian Federation.
PLoS One. 2016 Apr 7;11(4):e0152761. doi: 10.1371/journal.pone.0152761. eCollection 2016.
In the Arkhangelsk region of Northern Russia, multidrug-resistant (MDR) tuberculosis (TB) rates in new cases are amongst the highest in the world. In 2014, MDR-TB rates reached 31.7% among new cases and 56.9% among retreatment cases. The development of new diagnostic tools allows for faster detection of both TB and MDR-TB and should lead to reduced transmission by earlier initiation of anti-TB therapy.
The PROVE-IT (Policy Relevant Outcomes from Validating Evidence on Impact) Russia study aimed to assess the impact of the implementation of line probe assay (LPA) as part of an LPA-based diagnostic algorithm for patients with presumptive MDR-TB focusing on time to treatment initiation with time from first-care seeking visit to the initiation of MDR-TB treatment rather than diagnostic accuracy as the primary outcome, and to assess treatment outcomes. We hypothesized that the implementation of LPA would result in faster time to treatment initiation and better treatment outcomes.
A culture-based diagnostic algorithm used prior to LPA implementation was compared to an LPA-based algorithm that replaced BacTAlert and Löwenstein Jensen (LJ) for drug sensitivity testing. A total of 295 MDR-TB patients were included in the study, 163 diagnosed with the culture-based algorithm, 132 with the LPA-based algorithm.
Among smear positive patients, the implementation of the LPA-based algorithm was associated with a median decrease in time to MDR-TB treatment initiation of 50 and 66 days compared to the culture-based algorithm (BacTAlert and LJ respectively, p<0.001). In smear negative patients, the LPA-based algorithm was associated with a median decrease in time to MDR-TB treatment initiation of 78 days when compared to the culture-based algorithm (LJ, p<0.001). However, several weeks were still needed for treatment initiation in LPA-based algorithm, 24 days in smear positive, and 62 days in smear negative patients. Overall treatment outcomes were better in LPA-based algorithm compared to culture-based algorithm (p = 0.003). Treatment success rates at 20 months of treatment were higher in patients diagnosed with the LPA-based algorithm (65.2%) as compared to those diagnosed with the culture-based algorithm (44.8%). Mortality was also lower in the LPA-based algorithm group (7.6%) compared to the culture-based algorithm group (15.9%). There was no statistically significant difference in smear and culture conversion rates between the two algorithms.
The results of the study suggest that the introduction of LPA leads to faster time to MDR diagnosis and earlier treatment initiation as well as better treatment outcomes for patients with MDR-TB. These findings also highlight the need for further improvements within the health system to reduce both patient and diagnostic delays to truly optimize the impact of new, rapid diagnostics.
在俄罗斯北部的阿尔汉格尔斯克地区,新发病例中的耐多药结核病(MDR-TB)发病率位居世界前列。2014年,新发病例中的耐多药结核病发病率达到31.7%,复治病例中达到56.9%。新型诊断工具的开发有助于更快地检测结核病和耐多药结核病,并应通过更早开始抗结核治疗来减少传播。
PROVE-IT(验证影响证据的政策相关结果)俄罗斯研究旨在评估实施线性探针分析(LPA)作为基于LPA的诊断算法的一部分对疑似耐多药结核病患者的影响,重点关注从首次就诊到开始耐多药结核病治疗的治疗开始时间,而非将诊断准确性作为主要结果,并评估治疗结果。我们假设实施LPA将导致更快的治疗开始时间和更好的治疗结果。
将LPA实施前使用的基于培养的诊断算法与取代BacTAlert和罗氏培养基(LJ)进行药敏试验的基于LPA的算法进行比较。共有295例耐多药结核病患者纳入研究,163例通过基于培养的算法诊断,132例通过基于LPA的算法诊断。
在涂片阳性患者中,与基于培养(分别为BacTAlert和LJ)的算法相比,基于LPA的算法实施后耐多药结核病治疗开始时间的中位数分别减少了50天和66天(p<0.001)。在涂片阴性患者中,与基于培养(LJ)的算法相比,基于LPA的算法使耐多药结核病治疗开始时间的中位数减少了78天(p<0.001)。然而,基于LPA的算法仍需要数周时间才能开始治疗,涂片阳性患者为24天,涂片阴性患者为62天。与基于培养的算法相比,基于LPA的算法总体治疗结果更好(p = 0.003)。与基于培养的算法诊断的患者(44.8%)相比,基于LPA的算法诊断的患者在治疗20个月时的治疗成功率更高(65.2%)。基于LPA的算法组的死亡率(7.6%)也低于基于培养的算法组(15.9%)...
研究结果表明,引入LPA可使耐多药结核病的诊断时间更快、治疗开始更早,并且耐多药结核病患者的治疗结果更好。这些发现还凸显了卫生系统内进一步改进的必要性,以减少患者和诊断延误,从而真正优化新型快速诊断的影响。